Cancer Genetics this week launched an updated version of its MatBA-CLL/SLL test for mature B-cell neoplasms, which provides greater clarity of risk and outcomes for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
According to the Rutherford, NJ-based company, its microarray-based test now reports information on twenty genomic sites, enabling the stratification of CLL and SLL patients into three distinct risk categories: favorable, intermediate, and unfavorable.